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†“2011” Collaborative Innovation Center/Research Center of Neurobiology, Shanxi University of Traditional Chinese Medicine, Taiyuan
030619, China
‡Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, U.S.A.
§Institute of Neurology, Huashan Hospital, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University,
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Synopsis
Rho-Rho kinase (Rho-ROCK) triggers an intracellular signalling cascade that regulates cell survival, death, adhesion,
migration, neurite outgrowth and retraction and influences the generation and development of several neurological
disorders. Although Fasudil, a ROCK inhibitor, effectively suppressed encephalomyelitis (EAE), certain side effects
may limit its clinical use. A novel and efficient ROCK inhibitor, FSD-C10, has been explored. In the present study, we
present chemical synthesis and structure of FSD-C10, as well as the relationship between compound concentration
and ROCK inhibition. We compared the inhibitory efficiency of ROCKI and ROCK II, the cell cytotoxicity, neurite
outgrowth and dendritic formation, neurotrophic factors and vasodilation between Fasudil and FSD-C10. The results
demonstrated that FSD-C10, like Fasudil, induced neurite outgrowth of neurons and dendritic formation of BV-2
microglia and enhanced the production of neurotrophic factor brain-derived neurotrophic factor (BDNF), glial cell
line-derived neurotrophic factor (GDNF) and neurotrophin-3 (NT-3). However, the cell cytotoxicity and vasodilation of
FSD-C10 were relatively small compared with Fasudil. Although Fasudil inhibited both ROCK I and ROCK II, FSD-C10
more selectively suppressed ROCK II, but not ROCK I, which may be related to vasodilation insensitivity and animal
mortality. Thus, FSD-C10 may be a safer and more promising novel ROCK inhibitor than Fasudil for the treatment of
several neurological disorders.
Key words: Rho kinase, Rho kinase inhibitor, Fasudil, FSD-C10.
Cite this article as: Bioscience Reports (2015) 35, e00247, doi:10.1042/BSR20150032

INTRODUCTION
Rho kinase (ROCK), a serine/threonine kinase, is activated by
binding to the active GTP-bound form of the small GTPase Rho.
ROCK is expressed both centrally and peripherally where it is
implicated in fundamental cellular processes including migration, proliferation and survival [1]. The research in RhoA/ROCK
pathway has attracted much attention for more than a decade
since the discovery of ROCK in 1996. A series of studies have
demonstrated that the blockade of Rho/ROCK is considered to
be beneficial for inflammatory demyelination and degeneration
in the central nervous system (CNS) and has proved to be effic-

acious in animal models of stroke [2], multiple sclerosis (MS)
[3–6], amyotrophic lateral sclerosis (ALS) [7], Alzheimer’s disease (AD) [8] and Parkinson’s disease (PD) [9,10]. Therefore,
Rho/ROCK pathway is a promising therapeutic target in neurodegenerative and neurotraumatic diseases and ROCK inhibitor
should be a promising drug for preventing neurodegeneration
and stimulating neuroregeneration in several neurological diseases [11].
Fasudil
hydrochloride
[hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine monohydrochloride (HA 1077)]
is a isoquinoline sulfonamide derivative which is the most
commonly used for pharmacological ROCK inhibitor, both for
in vitro and in vivo studies. At present, Fasudil is only used
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Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; Arg-1, arginase-1; BDNF, brain-derived neurotrophic factor; CNS, central nervous system; ddH2 O,
double-distilled water; EAE. Encephalomyelitis; GDNF, glial cell line-derived neurotrophic factor; i.p., intraperitoneally; LDH, lactate dehydrogenase; MOG, mouse myelin oligodendrocyte
glycoprotein; MS, multiple sclerosis; NT-3, neurotrophin-3; p.i., post-immunization; PD, Parkinson’s disease; ROCK, Rho kinase.
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in clinic as a ROCK inhibitor for preventing and improving
the cerebral vasospasm after subarachnoid haemorrhage and
symptoms of cerebral ischaemia. Previous studies showed that
ROCK inhibitor also promotes the survival of neural stem cells,
axonal regeneration and differentiation of bone marrow mesenchymal cell into neurons [12,13]. Yamashita and colleagues [14]
observed that Fasudil can effect on neurons directly by reducing
the activity of ROCK and protect neuronal ischaemic damage in
persistent model of cerebral ischaemia.
When Fasudil displays certain beneficial effect, there are
many limitations in clinical use, including short-course treatment, low oral bioavailability, cell toxicity and blood pressure
fluctuation. Therefore, a considerable interest and efforts have
been devoted to the development of novel ROCK inhibitors that
should be taken orally for long-term use, with low cytotoxicity
and blood pressure fluctuation. We have designed a novel ROCK
inhibitor FSD-C10 that exhibits therapeutic potential in experimental autoimmune encephalomyelitis (EAE), an animal model
of MS. In the present study, we explored and compared the cell
cytotoxicity, neurite outgrowth and dendritic formation, neurotrophic factors, vasodilation and safety between Fasudil and
FSD-C10.

Primary neuron culture
Embryonic 18-day-mouse cortex (Shanghai SLAC Laboratory Animal Co. Ltd) were dissected under a microscope and
then triturated into the suspension in Neurobasal-A-medium
(Gibco) supplemented with 2 % B27 (Gibco), 100 units/ml penicillin and 100 μg/ml streptomycin (Gibco). The cells were then
plated on cover slips coated with poly-D-lysine (0.1 mg/ml;
Sigma) at a density of 1 × 106 cells per cm2 at 37 ◦ C in a
humidified cell incubator under a 95 %/5 % (v/v) mixture of
air and CO2, with the cell media being replaced every 48 h.
After 7 days, neurons were incubated with different conditioned
medium.

BV-2 microglial culture
The BV-2 immortalized microglial cell line [15] was purchased from ShenKe Biological Technology Co. and cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco),
supplemented with 10 % FBS (Gibco), 100 units/ml penicillin and 100 μg/ml streptomycin (Gibco) at 37 ◦ C in a humidified cell incubator under a 95 %/5 % (v/v) mixture of air and
CO2. Cells were plated on a 96-well plate at a density of
1.0 × 106 /ml (200 μl/well), on a 24-well plate at 1.0 × 106 /ml
(500 μl/well) and at 0.2 × 106 /ml (500 μl/well) for different
experiments.

MATERIALS AND METHODS
Evaluation of cell state
ROCK inhibition by mobility shift assay
The inhibition efficiency of Fasudil and FSD-C10 on ROCK
activity was measured by mobility shift assay with ATP concentration (Sigma) at 3.6 μM against ROCK I (Carna) and at 5.3 μM
against ROCK II (Carna) according to the manufacturer’s protocol. Staurosporine (Sigma) was used as positive control and
saline was used as negative control.
Fasudil and FSD-C10 were diluted to the final desired highest
compound concentration (10 μM) by 100 % DMSO and serially diluted on 96-well plate by transferring 30–60 μl of 100 %
DMSO in the next well for a total of 10 concentrations in duplicate. DMSO (100 μl) was added to two empty wells for no compound control and no enzyme control in the same 96-well plate.
Mobility shift assay was performed according to the manufacturer’s protocol. Briefly, compound Fasudil and FSD-C10 (10 μl)
were mixed with 90 μl of kinase buffer (50 mM HEPES, pH 7.5,
0.0 015 % Brij-35, 10 mM MgCl2 , 2 mM DTT) in 96-well plate.
The mixtures (5 μl) were incubated with 2.5× enzyme solution
(10 μl) in 384-well plate at room temperature for 10 min and
control was performed by adding 5 μl of kinase buffer. Substrate
solution (10 μl) was added at 28 ◦ C and the enzyme reaction
was stopped by adding 25 μl of stop solution (100 mM HEPES,
pH 7.5, 0.015 % Brij-35, 50 mM EDTA) to all wells.


max − conversion
× 100
Percent inhibition =
max − min
where max stands for DMSO control; min stands for low control.

We used two widely accepted assays, lactate dehydrogenase
(LDH) release and MTT reduction assay, for the measurement
of cell viability and death. These assays are considered reliable
and reproducible with high predictive validity and widely used
in various pharmacological studies [16].

MTT assay
Cell viability of BV-2 microglia and primary neurons was
detected by MTT assay. In brief, 100 μl of MTT solution
(0.5 mg ml − 1 , Duchefa) was added to cultured cells and incubated for an additional 4 h at 37 ◦ C, until the medium turned purple.
Absorbance at 570 nm was measured by a microplate reader after
addition of 100 μl DMSO. Each experiment was performed in
triplicate and repeated three times with separate cell preparations.
Results were expressed as a percentage of the control value at
570 nm.

LDH assay
The death of BV-2 microglia and primary neurons was measured
by LDH release in the culture medium. Levels of LDH release
in supernatants of cultured cells were measured using the cytotoxicity detection kit (Promega) according to the manufacturer’s
protocol. Maximum LDH release (A570 ) was determined following the treatment of cells with lysis buffer and considered as
control value (100 % LDH release). Data were expressed as a
percentage of the control value.

..........................................................................................................................................................................................................................................................................................................................................................................
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Animals

Western blot analysis

Female C57BL/6 mice (8–10 weeks old and 18–20 g of body
weight) were purchased from Vital River Laboratory Animal
Technology Co. Ltd. All experiments were conducted in accordance with the guidelines of the International Council for Laboratory Animal Science. The study was approved by the Ethics
Committee of Shanxi Datong University. All mice were housed
under pathogen-free conditions and maintained in a reversed 12:
◦
12-h light/dark cycle in a temperature controlled room (25 +
− 2 C)
for 1 week prior to experimental manipulation.

Protein from brains was homogenized on ice with an extraction
kit and protein concentration was determined by a Bradford protein assay. Protein extracts (30 μg) were separated by SDS/PAGE
and transferred on to a PVDF membrane (Immobilon-P; Millipore Corp.). The membranes were then incubated with antiGDNF (glial cell line-derived neurotrophic factor; 1:1000, Epitomics), anti-BDNF (brain-derived neurotrophic factor; 1:1000,
Promega), anti-NT-3(neurotrophin-3; 1:1000, Epitomics), antiNogo(1:1000, Epitomics), anti-iNOS (inducible nitric oxide synthase) (1:1000, Cell Signaling Technology) Enzo Life Sciences,
anti-arginase-1 (Arg-1) (1:1000, BD Bioscience) and anti-βactin (1:10000, Cell Signaling Technology) for overnight at 4 ◦ C.
Bands were visualized by horseradish peroxidase (HRP-) conjugated secondary antibodies and ECL kit under ECL system (GE
Healthcare Life Sciences).

Induction and clinical evaluation of EAE
Mouse myelin oligodendrocyte glycoprotein peptide 35–55
(MOG35–55 , MEVGW YRSPFSRVVHLYRNGK) was produced
in an automatic synthesizer (CL. Bio-Scientific Company). The
purity of the peptide was >95 % as determined by HPLC. Chronic
EAE was induced by subcutaneous immunization on the upper
dorsal flanks with 300 μg of MOG35–55 in Freund’s complete adjuvant (Sigma) supplemented with 3 mg/ml of M. Tuberculosis
H37Ra (BD Difco; 400 mg/mice). Mice were injected intraperitoneally (i.p.) with 500 ng of pertussis toxin (Enzo Life Sciences)
on days 0 and 2 post-immunization (p.i.). Animals were weighed
and evaluated for clinical score every other day in a blinded
fashion by at least two investigators. Clinical score of EAE was
graded according to the following criteria: 0: healthy; 1: limp tail;
2: ataxia and/or paresis of hind limbs; 3: paralysis of hind limbs
and/or paresis of forelimbs; 4: tetraparalysis; and 5: moribund
or death. When the clinical score of EAE reaches 3, we give
suitable care including softening of food with water in dish and
additional nutrients such as egg, making mice easy to obtain food
and nutrition.

Administration of Fasudil and FSD-C10
Mice were divided into three groups: Fasudil-treated group
(n = 8), FSD-C10-treated group (n = 8) and double-distilled water (ddH2 O) EAE control group (n = 9). Fasudil or FSD-C10
(from Tianjin Chase Sun Pharmaceutical Co.) was dissolved in
sterile ddH2 O. Mice were i.p. injected with 800 μg/200 μl/daily
from day 3 to day 27 p.i. Mice that received the same volume of
ddH2 O i.p. served as control.

Assessment of neurite outgrowth and dendritic
length
Fluorescent photomicrographs of neurons with microtubuleassociated protein-2 (MAP-2) staining or photomicrographs
of BV-2 cells under inverted microscope were captured with
a 20× objective and a digital camera of Olympus microscope.
Images were acquired from randomly selected fields for each
group. The length of the longest neurite outgrown or dendritic
formation in the cell body was measured by an investigator
blinded to the experimental groups using a public-domain
image-processing program (Image J, http://rsb.info.nih.gov/ij).
Average lengths of neuronal neurite or dendritic formation were
used for quantification.

The test of vasodilation
Both Fasudil and FSD-C10 were dissolved in sterile ddH2 O and
the concentration was 4 mg/ml. Naive female C57BL/6 mice
were i.p. injected with 200 μl of Fasudil or FSD-C10 and the
pictures of limbs were taken at 30 and 60 min after drug injection.

Statistical analysis
All the experiments were repeated two or three times and GraphPad Prism software was used for statistical analysis. Student’s
ttest was performed to analyse the difference between any two
groups. A statistically significant difference was assumed at
P < 0.05.

RESULTS
Chemical synthesis and structure of FSD-C10
In 2004, Takami et al. [17] reported a ROCK ligand-binding
pocket model that is divided into three parts: region A, region
F and region D (Figure 1a). It was speculated that the nitrogen
atom of region D of Fasudil on the homopiperazine moiety might
form a similar hydrogen bond with ATP, which could improve
the bioactivity of the compound. Therefore, we designed and
synthesized an isoquinoline ROCK inhibitor FSD-C10 targeting
region D of Fasudil as the lead compound and on the basis of
ligand-binding pocket theory (Figure 1b).

The inhibition of ROCK by Fasudil and FSD-C10
Figure 2 shows the relationship between compound concentration and percentage of ROCK inhibition. As shown in Table 1,
the inhibition of ROCK activity (IC50 ) was measured with
ATP concentration at 3.6 μM against ROCK I and at 5.3 μM
against ROCK II and observed in Fasudil (ROCK I = 385 nM;
ROCK II = 344 nM) and FSD-C10 (ROCK I = 1141 nM;
ROCK II = 711 nM) as compared with negative controls

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 1

Synthesis of FSD-C10
(a) Ligand-binding pocket of ROCK homology model and (b) chemical substructures designated for each division of the
ligand-binding pocket that are reproduced from [17]: Takami, A., Iwakubo, M., Okada, Y., Kawata, T., Odai, H., Takahashi,
N., Shindo, K., Kimura, K., Tagami, Y., Miyake, M. et al. (2004) Design and synthesis of Rho kinase inhibitors. Bioorg.
Med. Chem. 12, 2115–2137. The pocket is divided into three parts: region A, F and D. The pocket D region is cleft-like
in shape and a wide range of chemical fragments would fit this cleft [17]. Therefore, we designed and synthesized an
isoquinoline FSD-C10 targeting region D of the Fasudil. (c) Synthetic process of FSD-C10. (a) CH2 Cl2 , saturated sodium
bicarbonate solution, 0 ◦ C. (b) CH2 Cl2 , Et3 N, 2 h, 0 ◦ C, 95 % yield. (c) CH2 Cl2 , reflux, 7 h, 75 % yield.

Table 1 The inhibition efficiency of Fasudil and FSD-C10 on
ROCK activity
Compound

Unit (nM)

ROCK I ATP
con. (3.6 μM)

ROCK II ATP
con. (5.3 μM)

Fasudil

IC50

385

FSD-C10

IC50

1141

711

Positive control

IC50

1.7

0.93

Negative control

IC50

>10000

344

>10000

(ROCK I > 10000; ROCK II > 10000). However, the inhibitory efficiency of FSD-C10 on ROCK activity was weaker than
that of Fasudil, especially in ROCK I activity (Table 1).

The therapeutic effect of Fasudil and FSD-C10 in
EAE
In the present study, mice were immunized with MOG35-55
peptide to develop an EAE model that closely imitates many
characteristics of MS. Starting on day 3 p.i., mice received
800 μg/200 μl daily of Fasudil or FSD-C10 until on day 27
p.i. by i.p. injection. As shown in Figure 3, maximum clinical score in EAE control group (n = 9) was 2.78, mean clin-

ical score was 1.29 +
− 1.08 compared with mice injected with
Fasudil (n = 8, maximum clinical score = 0.19; mean clinical score = 0.04 +
− 0.07, P < 0.001) and FSD-C10 (n = 8, maximum clinical score = 0.50; mean clinical score = 0.28 +
− 0.23,
P < 0.001). There is a relationship between loss of body weight
and severity of clinical score during the development of EAE.
The treatment of Fasudil or FSD-C10 had less body weight loss
as compared with that of EAE mice (Figure 3, both P < 0.001).

The effect of Fasudil and FSD-C10 on cell viability
and death
Cell viability and death after culture with Fasudil or FSDC10 were determined by the MTT and LDH assays (Figure 4).
Low/medium-dose Fasudil or FSD-C10 (ranging 0.6–15 μg/ml)
did not influence the viability and death of cultured primary neurons, whereas high concentration of Fasudil (75 μg/ml) caused a
significant decrease in neuron viability (P < 0.05) and neuron
death (P < 0.05). In contrast, the same concentration of FSDC10 did not lead to significant decrease in neuron viability and
death compared with control (Figure 4a).
Similarly, low/medium-dose Fasudil or FSD-C10 (ranging
0.6–15 μg/ml) did not influence the viability and death of BV-2

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 2

The relationship between compound concentration and ROCK inhibition
Fasudil and FSD-C10 were diluted to the final desired highest compound concentration (10 μM) by 100 % DMSO and
serially diluted on 96-well plate by transferring 30–60 μl of 100 % DMSO in the next well for a total of 10 concentrations in
duplicate. DMSO (100 μl) was used for no compound control and no enzyme control. Percentage of ROCK inhibition was
calculated by ( max−conversion
) × 100. ‘Max’ stands for DMSO control; ‘min’ stands for low control.
max−min

Figure 3

Fasudil and FSD-C10 ameliorated the severity of EAE
Chronic EAE was induced in C57BL/6 mice with MOG35–55 peptide. Mice received Fasudil or FSD-C10 by i.p. injection
from day 3 to 27 p.i. Mean clinical score and mean body weight were recorded. The comparison in each time point was
separately analysed by Mann–Whitney U test after non-parametric Kruskal Wallis test.

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 4

The viability and death of primary neurons (a) and BV-2 microglia (b) in vitro
Cell viability was measured using the MTT assay and cell death was detected by LDH release assay. Primary neurons and
BV-2 microglia were treated with different concentrations of Fasudil or FSD-C10 (0.6, 3, 15 and 75 μg/ml) for 24 h. The
quantitative data are mean +
− S.E.M. based on three independent experiments with similar results; *P < 0.05.

microglia, whereas high concentration of Fasudil (75 μg/ml)
caused a significant decrease in BV-2 cell viability (P < 0.05) and
death (P < 0.05). In contrast, FSD-C10 (75 μg/ml) did not lead
to significant decrease in BV-2 cell viability and death compared

with control (Figure 4b). As expected, BV-2 microglia treated
with higher concentration of Fasudil (75 μg/ml and 200 μg/ml)
exhibited obvious cell death after 48 h culture, whereas FSDC10-exposed cells at similar concentrations showed a good cell

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 5

Fasudil and FSD-C10 promoted neurite outgrowth in primary neurons and dendritic formation in BV-2 microglia
The neurite length of primary neurons (a) and the dendritic length of BV-2 microglia (b) was examined with an inverted
Olympus microscope. (c) High concentrations of Fasudil (75 and 200 μg/ml), but not FSD-C10, caused significant breakage
of neurite outgrowth. The length of the longest neurite outgrown or dendritic formation in the cell body was measured
by a public-domain image-processing program The quantitative data are mean +
− S.E.M. based on three independent
experiments with similar results; **P < 0.01, ***P < 0.001.

morphology (Figure 4c). However, higher doses of FSD-C10
(200 μg/ml) also caused cell death with the extension of time
(result not shown). The results show that FSD-C10 cytotoxicity
is lower than Fasudil in in vitro experiments.

The effect of Fasudil and FSD-C10 on neurite
outgrowth of neurons and dendritic formation of
BV-2 microglia
ROCK has a key role in blocking axon growth and pharmacological ROCK inhibition using small molecules inhibit-

ors has shown to increase axonal regeneration [18,19]. We
next explored the effect of Fasudil and FSD-C10 on neurite outgrowth of primary neurons and dendritic formation
of BV-2 microglia. As shown in Figure 5(a), the neurite length of primary neurons was significantly prolonged
after the treatment of Fasudil (mean = 6.6 μm) and FSD-C10
(mean = 10.5 μm) as compared with PBS control (4.1 μm, both
P < 0.01).
The dendritic length of BV-2 microglia was also significantly prolonged after the treatment of Fasudil (mean = 12.5 μm)
and FSD-C10 (mean = 12.5 μm) as compared with PBS

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 6

The effect of Fasudil and FSD-C10 on neuronal growth factors
Chronic EAE was induced in C57BL/6 mice with MOG35–55 and treated with Fasudil or FSD-C10. On day 28 p.i., brains were
harvested to prepare protein for the expression of BDNF (a), GDNF (b), NT-3 (c) and Nogo (d) by Western blot. The results
+ S.E.M. of six
were expressed as the fold change relative to β-actin as the loading control. Quantitative results are mean −
mice in each group. *P < 0.05.

control (2.94 μm, both P < 0.001; Figure 5b). These results indicate that FSD-C10, like Fasudil, exhibited the basic characteristics of ROCK inhibitor, contributing to the neurite outgrowth
of neurons and dendritic formation of BV-2 microglia. However,
high concentrations of Fasudil (75 and 200 μg/ml) caused significant breakage of dendritic branches (blue arrow), whereas
FSD-C10, even at the high concentrations (75 and 200 μg/ml),
did not cause significant breakage of dendritic branches on BV2
microglia (Figure 5c).

The role of Fasudil and FSD-C10 on neurotrophic
factors
Previous data suggest that the neurotrophic and neuroprotective
molecules directly or/and indirectly contribute to neurite outgrowth of neurons. In the present study, we explored the role of
Fasudil and FSD-C10 on production of the neurotrophic factors
in vivo. Administration of Fasudil or FSD-C10 significantly enhanced expression of BDNF, GDNF and NT-3 proteins in brain
compared with control EAE mice (Figures 6a–6c, all P < 0.05).

..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 7

Fasudil and FSD-C10 shifted M1 to M2 phenotype
Chronic EAE was induced in C57BL/6 mice with MOG35–55 and treated with Fasudil or FSD-C10. On day 28 p.i., brains
were harvested to prepare protein for the expression of iNOS and Arg-1 by western blot. The results were expressed as
the fold change relative to β-actin as the loading control. Quantitative results are mean +
− S.E.M. of six mice in each group;
*P < 0.05.

In contract, Fasudil or FSD-C10 administration slightly, although
not significantly, declined the expression of Nogo protein level in
brain (Figure 6d). These results reveal that the neurite outgrowth
of neurons and dendritic formation of BV-2 microglia could be
related to increased neurotrophic factors.

The role of Fasudil and FSD-C10 on the polarization
of microglia/macrophages
The classical M1 polarization of macrophages/microglia has been
linked with promoting inflammation, whereas the M2 phenotype
is anti-inflammatory and promotes tissue repair [1]. Our previous
studies clearly demonstrated that Fasudil can convert M1 microglia/macrophages to M2 cells [5,6]. iNOS and Arg-1 are two
representatives of M1 and M2 microglia/macrophages respectively and we thus measured their expression in brain of EAE
treated with Fasudil or FSD-C10. The results showed that FSDC10, like Fasudil, inhibited iNOS expression and elevated Arg-1
expression in brain of EAE mice (Figure 7), indicating that FSDC10, like Fasudil, also converts inflammatory M1 cells toward
anti-inflammatory M2 cells in vivo, which is consistent with the
decrease in inflammatory cytokines described above.

The influence of Fasudil and FSD-C10 on
vasodilation and mortality
The vasodilation and the fluctuation of blood pressure is a side effect and thus limits the long-term use of ROCK inhibitor Fasudil
in the nervous system diseases, especially in chronic progressive disorders. We thus compared the role of Fasudil and FSDC10 on the vasodilation in healthy mice. The results showed

that an obvious vasodilation after 30 and 60 min on the foot of
mice was observed in mice that were i.p. injected with Fasudil
(800 μg/mouse) compared with mice injected with FSD-C10 at
the same dose (Figure 8a), revealing that FSD-C10 has a relatively weak vasodilator effect in mice. Simultaneously, the injection of Fasudil (1600 and 2000 μg/mouse/i.p) caused nearly
33 %–67 % mortality within 2 h, whereas none of the mice injected with FSD-C10 died (Figure 8b). Given that FSD-C10 was
well tolerant in vivo, further pre-clinical studies are valuable for
the treatment of MS.

DISCUSSION
Based on two reasons: (1) ROCK inhibitor should be a promising drug target for preventing neurodegeneration and stimulating neuroregeneration in stroke patients and animal models of
stroke, MS, ALS, AD and PD and (2) ROCK inhibitor Fasudil in
clinical practice exhibits the following limitations, including a relatively narrow safety window, not suitable for long-term use and
poor oral bioavailability, researchers are looking for novel ROCK
inhibitors that are more efficient, safer, oral and for long-term use
for the treatment of neurological disorders. Our previous studies have demonstrated that a novel ROCK inhibitor FSD-C10
ameliorated the clinical severity of EAE, accompanied by improvement of demyelination and the inhibition of inflammatory
cells in the CNS of EAE mice, exhibiting the therapeutic effect in
EAE [20]. In the present study, we further compared therapeutic
potential, the inhibitory efficiency of ROCK, the cell cytotoxicity,
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Figure 8 The influence of Fasudil and FSD-C10 on vasodilation
and mortality
(a) After i.p. injection of FSD-C10 or Fasudil, we observe the vasodilation
of mice limbs was observed after 30 and 60 min. A representative of
three mice each group is shown. (b) After i.p. injection of FSD-C10
or Fasudil at 800, 1600 and 2000 μg/mouse, animal mortality was
recorded with 2 h.

neurite outgrowth and dendritic formation, neurotrophic factors
and vasodilation between Fasudil and FSD-C10. Our results first
demonstrated that FSD-C10 and Fasudil exerted comparable effect in ameliorating the clinical severity of EAE. Both Fasudil
and FSD-C10 induced neurite outgrowth of primary neurons and
dendritic formation of BV-2 microglia as well as the production of
neurotrophic factor BDNF, GDNF and NT3. Importantly, FSDC10 treatment in cultured cells and in healthy mice exhibited
relatively low cell cytotoxicity and vasodilation respectively, as
compared with Fasudil, thus being safer for clinical application.
Consistent with previous findings that the inhibition of ROCK
contributes to the neurite outgrowth of neurons [18], our results also showed that both Fasudil and FSD-C10 induced neurite
outgrowth of neurons, as well as dendritic formation of BV-2
microglia. The neurite outgrowth is not only a result of a simple
expansion and proliferation of neuronal cells, but also entails the
neuronal plasticity that is highly dependent on the microenvironment, in which neurotrophic factors promote neurite outgrowth

from cultured adult rat dorsal root ganglion (DRG) neurons[21].
One of them is an involvement of guidance molecules that attract
or repulse growing neurite depending on the nerve cell and receptor types. In our study, the expression of three neurotrophic
factor BDNF, GDNF and NT-3 was induced by Fasudil or FSDC10, revealing that neurotrophic factor signalling axis may be a
mechanism in neurite outgrowth of primary neurons and dendritic
formation of BV-2 microglia.
BDNF is a neurotrophin involved in neuronal survival, differentiation and function, axonal growth and dendritic plasticity in
the CNS [22]. BDNF was shown to exert neuroprotective effects
in several experimental models of neurological diseases [23–25].
The importance of BDNF for brain function and maintenance is
underscored by the fact that BDNF-deficient mice already die
during the first weeks of life [26]. Even heterozygous mice with
50 % reduced levels of BDNF expression display some behavioural deficits such as aggressiveness, hyperactivity, hyperphagia
and obesity [27–29]. GDNF has also been found to be involved in
a considerable number of effects in the nervous system, including
the survival, migration, differentiation and neurite outgrowth of
neurons [30]. NT-3 is a growth factor that modulates glial cell
biology and myelination in the CNS and promotes oligodendrocyte precursor proliferation, survival and differentiation [31–33].
Further, NT-3 has significant capacity to provide neuroprotection and reduce astrogliosis, which is an important mechanism
underlying the formation of MS plaque [34]. When applied to
spinal cord injury, NT-3 overexpression promoted remyelination, axonal regeneration and functional recovery [25]. Following transplantation of NT-3 transduced neural stem cells, NT-3
probably acted not only on donor cells in an autocrine fashion,
but also on host cells (paracrine) to enhance neuronal differentiation of both transplanted and endogenous cells and effectively
suppressed EAE [35]. In addition, mouse helper T 2 (Th2), but
not Th1 cells, expressed a high-affinity receptor for NT-3 and
adding NT-3 to cultured Th2 cells to produce a large amount
of Interleukin 4 (IL-4) [36], suggesting a direct link between
immunomodulation, neuroprotection and therapeutic effects in
CNS inflammatory demyelination [37]. Taken together, a set of
experiments clearly demonstrate that neurotrophic factor BDNF,
GDNF and NT-3 are able to provide excellent environment for
neurite outgrowth of neurons that will be ultimately useful for
the neural repair and regeneration purposes [38,39].
The role of the Rho/ROCK/LIM domain kinase (LIMK) pathway in neurite outgrowth has been addressed in numerous studies,
but the specific contribution of single members of this cascade
remained insufficiently understood. Previous studies indicated
the inability of adult mammalian CNS axons to regenerate after
injury, partly due to the presence of myelin-associated neurite outgrowth inhibitors, including Nogo, myelin-associated glycoprotein (MAG) and MOG. These molecules combine to the same
receptor complex and activate downstream signalling molecules,
causing the inhibition of neurite growth [40,41]. Rho and ROCK
have been identified as downstream signalling molecules of these
neurite growth inhibitors and are key elements for neurite growth
inhibition and growth cone collapse elicited by these inhibitors
[42]. In the present study, the inhibition of ROCK by Fasudil or
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FSD-C10 slightly, not significantly though, declined the expression of Nogo. Further studies are necessary to fully evaluate the
role of FSD-C10 in the neuroprotection and neuroregeneration.
In addition, ROCK appears to mediate the vasoconstrictor effects and is involved in the regulation of nitric oxide (NO) pathway [43], thus contributing to the maintenance of basal vascular
tone [44] and possibly participating in the pathogenesis of human
hypertension [45]. Both ROCK I and II are highly homologous
and share more than 20 immediate downstream substrates [46].
Two isoforms of ROCK I and II are expressed in vascular smooth
muscle cells and inhibit myosin light-chain phosphatase (MLCP)
activity [47], whereas ROCK I appears to play a predominant
role in vascular inflammation [48]. Additionally, a critical role for
ROCK I in mediating cardiac fibrosis was also observed [49]. The
activation of Rho/ROCK I signalling disrupts the translocation
of occluding/zona occulden-1 (ZO-1), which are the major components of endothelial tight junction. Therefore, we hypothesize
that the insensitivity of vascular dilatation in FSD-C10-injected
mice may be related to a relatively weak inhibition of ROCK I
compared with Fasudil, thus avoiding potential side effect of the
latter. Indeed, the role of FSD-C10 in relation to bioavailability,
subsequent vascular remodelling and therapeutic potential is still
a worthy of further investigation.
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